Should You Buy Danaher Stock at Its All-Time High?
Another quarter, and more mid-single-digit core revenue growth for Danaher (NYSE: DHR). The company is seeing long-term benefits from the COVID-19 pandemic, and the acquisition of General Electric's biopharma business (now called Cytiva) has come out of the gate strong. There's a lot to like about the company, so let's take a look at the results and the investment proposition with the stock.
Second-quarter results were always going to be affected by the integration of Cytiva, but very few investors could have expected such a strong opening for the business. Reported revenue rose 19% with a core revenue increase (including Cytiva) of 3.5%.
Image source: Getty Images.
Source Fool.com
